v3.24.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 46,453 $ 25,841
Short-term investments 20,736 25,884
Restricted cash 146 146
Accounts receivable 1,335 34,108
Inventories 13,980 9,706
Other current assets 9,205 6,184
Total current assets 91,855 101,869
Property and equipment, net 1,661 3,856
Operating lease assets 45,833 54,935
Other assets 3,357 4,844
Total assets 142,706 165,504
Current liabilities:    
Accounts payable 2,146 3,684
Accrued compensation 7,768 11,519
Accrued research and development expenses 6,077 17,364
Deferred revenue 116,344 77,833
Other current liabilities 23,644 31,826
Total current liabilities 155,979 142,226
Deferred revenue - long-term 470 37,562
Operating lease liabilities - long-term 35,243 45,693
Liability related to the sale of future revenues - long-term 37,584 34,623
Other long-term liabilities 3,969 4,631
Total liabilities 233,245 264,735
Commitments and contingencies (Note 8)
Stockholders' equity (deficit):    
Common stock- $0.0001 par value, 500,000 shares authorized as of September 30, 2024 and December 31, 2023; 5,740 and 4,258 shares issued an outstanding as of September 30, 2024 and December 31, 2023, respectively 1 0
Additional paid-in capital 1,951,298 1,870,123
Accumulated other comprehensive (loss) income 22 (204)
Accumulated deficit (2,041,860) (1,969,150)
Total stockholders' equity (deficit) (90,539) (99,231)
Total liabilities and stockholders' equity (deficit) $ 142,706 $ 165,504

Source

10-Q
HTML PDF
XBRL
ZIP